The 8 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 17.00, with a high estimate of 30.00 and a low estimate of 13.00. The median estimate represents a +214.81% increase from the last price of 5.40.
The current consensus among 8 polled investment analysts is to Buy stock in Aldeyra Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.34
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.